In this randomized , double-blind , placebo-controlled , multicenter trial ( ClinicalTrials.gov NCT00797667 ) , patients experiencing 3-14 migraine days during a 4-week baseline were randomized to telcagepant 140 mg , telcagepant 280 mg , or placebo twice daily for 12 weeks .